

A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harboursing NTRK Gene Abnormalities

NCT07394374

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Cullgen (Shanghai), Inc
Enrollment	42 participants

Key Eligibility Criteria

Inclusion (22)

- Age ≥18 when signing the informed consent form, regardless of gender.
- The estimated survival time is ≥3 months.
- Histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors that have failed, are intolerant to, or have no available standard therapy.
- Dose Escalation Phase: While testing for NTRK/TRK status is not mandatory, enrollment priority will be accorded to patients whose tumors harbor oncogenic NTRK/TRK alterations. Dose Expansion and Indication Expansion Phases: Enrollment eligibility is contingent upon the confirmation of oncogenic NTRK/TRK alterations, as ascertained through tumor tissue or peripheral blood testing.
- The Indication Expansion Phase will enroll subjects into the following three cohorts, with respective entry criteria:
... and 17 more (see full listing online)

Locations (6 total)

The Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
West China Hospital of Sichuan University, Chengdu, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
... and 3 more locations